ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-49.1	-54.37	-34.68	-20.24	-1.07
Depreciation & Amortization	0.06	0.07	0.03	0.21	0.01
Other Amortization	-	-	-	-	0
Asset Writedown & Restructuring Costs	-	-	1.06	-	-
Loss (Gain) From Sale of Investments	-7.47	-6.88	0.29	-	-
Stock-Based Compensation	12.55	9.24	5.84	2.83	3.54
Other Operating Activities	-	-	0.14	-0	0.12
Change in Accounts Payable	-0.13	-2.78	-10.29	0.97	1.19
Change in Unearned Revenue	-	-3.14	-1.32	-2.51	6.96
Change in Other Net Operating Assets	-0.81	-1.42	-1.15	1.18	-1.69
Operating Cash Flow	-45.86	-59.27	-40.08	-17.56	9.07
Capital Expenditures	-0.17	-0.18	-0.2	-0.06	-
Investment in Securities	24.37	-87.01	-	-	-
Investing Cash Flow	21.7	-87.18	-0.2	-0.06	-
Long-Term Debt Issued	-	-	-	-	5
Long-Term Debt Repaid	-	-	-8.68	-1.82	-
Net Debt Issued (Repaid)	-	-	-8.68	-1.82	5
Issuance of Common Stock	3.29	6.9	0.57	0.17	0.1
Other Financing Activities	-	-	198.84	-	-
Financing Cash Flow	3.29	6.9	190.73	53.16	5.1
Net Cash Flow	-20.88	-139.55	150.46	35.54	14.17
Free Cash Flow	-46.03	-59.44	-40.28	-17.62	9.07
Free Cash Flow Margin	-1792.48%	-198136.67%	-3060.56%	-319.94%	50.86%
Free Cash Flow Per Share	-0.48	-0.62	-1.01	-0.61	0.45
Cash Interest Paid	-	-	0.37	0.58	0.33
Levered Free Cash Flow	-21.21	-36.17	-17.86	-9.57	-
Unlevered Free Cash Flow	-21.21	-36.17	-17.86	-9.07	-
Change in Net Working Capital	-4.17	3.11	2	-0.11	-

Source: S&P Capital IQ. Standard template. Financial Sources.